Quantification of Human Cytomegalovirus DNA in Bone Marrow Transplant Recipients by Real-Time PCR
Open Access
- 1 December 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (12) , 4362-4369
- https://doi.org/10.1128/jcm.39.12.4362-4369.2001
Abstract
A real-time PCR assay was developed to quantify human cytomegalovirus (CMV) DNA in peripheral blood leukocytes (PBLs) of bone marrow transplantation patients. Unlike other teams, we quantified CMV and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene using a plasmid containing both sequences as an external standard. Tenfold serial dilutions of this plasmid yielded overlapping standard curves that allowed the quantification of CMV and GAPDH gene copies in an efficient and accurate manner. Sequential blood samples (164 specimens) were collected from 16 patients. PBLs were tested by the pp65 antigenemia assay and quantitative CMV and GAPDH gene PCRs. CMV DNA was detected by PCR in 13 patients a mean of 15 days prior to the appearance of antigenemia. The administration of anti-CMV drugs led to a rapid decrease in the numbers of viral copies and positive nuclei. Real-time PCR assay results correlated with those of the CMV pp65 antigenemia assay ( P < 0.00001). The TaqMan assay may be a useful tool for rapid quantification of CMV infection and for monitoring of CMV reactivation in bone marrow transplantation recipients.Keywords
This publication has 20 references indexed in Scilit:
- Quantification of Human Cytomegalovirus DNA by Real-Time PCRJournal of Clinical Microbiology, 2001
- Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplantBone Marrow Transplantation, 1998
- Value of cytomegalovirus detection by PCR in bronchoalveolar lavage routinely performed in asymptomatic bone marrow recipientsBone Marrow Transplantation, 1997
- Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation?British Journal of Haematology, 1997
- Low correlation of human cytomegalovirus DNA amplification by polymerase chain reaction with cytomegalovirus disease in organ transplant recipientsJournal of Medical Virology, 1994
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Human Cytomegalovirus Infection of the Major Leukocyte Subpopulations and Evidence for Initial Viral Replication in Polymorphonuclear Leukocytes from Viremic PatientsThe Journal of Infectious Diseases, 1992
- Phase I-II Trial of Foscarnet for Prevention of Cytomegalovirus Infection in Autologous and Allogeneic Marrow Transplant RecipientsThe Journal of Infectious Diseases, 1992
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow TransplantsNew England Journal of Medicine, 1991